Misleading released two sets of data for the same trial, and the stock plummeted because it turned out he had released post-hoc data. Until last month, he insisted the trial met all endpoints, but now he's claiming it only met one primary endpoint. Who would trust such a blatant liar?
NWBO followed the same playbook of releasing data in a journal two years after data lock (which was a joke). Nobody seems to care about peer review; after all, peer review is meant for research, not for FDA approval and commercialization.
Market Data 
Markets 
